Male and Female Pattern Hair Loss: Treatable and Worth Treating

This article discusses the potential genetic basis of central centrifugal cicatricial alopecia in women of African ancestry but does not provide new research results.

This article reviews the clinical assessment of female pattern hair loss and discusses up-to-date treatments, highlighting oral minoxidil combined with oral spironolactone as a promising novel therapy. It emphasizes the crucial role of general practitioners in diagnosis, treatment planning, and managing associated psychosocial issues.

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.

In this study, researchers evaluated the hair pull test and found that normal values should be reduced to two hairs or fewer, with no significant impact from hair washing, brushing, or lifestyle factors such as hair texture and medication use.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This study identified a new variety of central centrifugal cicatricial alopecia that includes patchy hair loss on the lateral and posterior scalp in African-American women, which could be misdiagnosed as traction alopecia without dermatoscopy and pathology.

This pilot study suggests injecting platelet-derived growth factors into the scalp may offer some clinical benefits for androgenetic alopecia, though further randomized trials are needed for confirmation.

This study found that low-level laser treatment with the HairMax Lasercomb significantly increased terminal hair density in both men and women with pattern hair loss, with no serious adverse events reported.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

This article reviews emerging treatments for androgenetic alopecia, including topical 5-alpha-reductase inhibitors and prostaglandin modulators, but reports no clinical results and calls for further efficacy evidence, especially for PRP.

This study found that low-level light therapy significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, suggesting it could be an effective treatment option.

This study found that adding microneedling to minoxidil treatment significantly improved hair growth in men with androgenetic alopecia compared to minoxidil alone across all assessed measures.

This review found evidence supporting the effectiveness and safety of topical minoxidil for treating female pattern hair loss, though many included studies were at high risk of bias.

This review discusses the dermoscopic features of common hair and scalp disorders and reports no new clinical results, aiming to assist dermatologists in diagnosing conditions like tinea capitis and alopecia areata.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

This study found that patients with alopecia perceive their hair loss as more severe than dermatologists do, and their own ratings of hair loss severity better reflect their quality of life impacts.

This review explores the current understanding of genetic and hormonal influences on male androgenetic alopecia and female pattern hair loss, providing guidance for clinicians but reports no new results.

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

This case report describes a patient with complete androgen insensitivity syndrome experiencing female pattern hair loss, suggesting that factors beyond direct androgen action may contribute to this condition in women.

In this study, genetic variation in the CYP19A1 gene, particularly the common rs4646 C allele, was associated with an increased risk of female pattern hair loss, especially in women under 40.

This review discusses the advantages and limitations of various hair loss evaluation methods but reports no new results; it emphasizes the importance of cautious interpretation for these diagnostic tools.

This study found that the HairMax LaserComb® significantly increased hair density and was safe and well tolerated for treating androgenetic alopecia in men compared to a sham device.

This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This study evaluated the effect of 2% ketoconazole lotion for androgenetic alopecia, but the results regarding its effectiveness on clinical appearance remained unclear.

In this study of men with androgenetic alopecia, daily finasteride 1 mg alongside hair transplant improved scalp hair density and growth of nontransplanted hair compared to placebo over 48 weeks.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

This article reviews the historical developments in understanding and treating male pattern hair loss, emphasizing the role of dihydrotestosterone and 5α-reductase inhibitors, but reports no new clinical findings.

This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.

This study reports that oral finasteride improved or stabilized hair loss in women with hyperandrogenism but not in postmenopausal women with female pattern hair loss.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

In this study, finasteride 1 mg/day for 12 months did not improve hair growth or slow hair thinning in postmenopausal women with androgenetic alopecia compared to placebo.

This review discusses the psychological and social impacts of androgenetic alopecia and suggests that medical treatments can have some positive psychological effects, highlighting the condition's moderate stress and impact on body image.

This article highlights a specific, yet largely unrecognized, sign that aids in diagnosing androgenetic alopecia in women, emphasizing its practical application in clinical settings.

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

This study analyzed survey responses from 800 alopecia areata patients and found a possible genetic association with increased insulin-dependent diabetes mellitus in relatives but not in the patients themselves.

This article presents a classification system for stages of female-pattern androgenetic alopecia to aid early diagnosis and mentions existing systems for rare male-pattern cases, but reports no new clinical results.